Literature DB >> 7807144

Excitotoxicity and motor neurone disease: a review of the evidence.

P J Shaw1.   

Abstract

Excitotoxic mechanisms have a well established role in the pathogenesis of neuronal injury following acute CNS insults such as ischaemia and trauma. Their role in the selective cell death which occurs in chronic neurodegenerative disorders such as motor neurone disease (MND) is more speculative. The traditional classification of glutamate receptor subtypes which mediate excitotoxicity requires modification in the light of new molecular data. There is much greater structural and functional diversity in this receptor family than previously envisaged and it is quite possible that specific populations of neurones will be characterised by a unique profile of glutamate receptor subtypes which may be a factor determining their selective vulnerability. The molecular mechanisms underlying excitotoxic neuronal injury are still being elucidated but it is clear that the cascade of events resulting from elevation of intracellular free calcium is likely to play a major role. As well as being a primary mechanism of neuronal injury, excitotoxicity can secondarily damage neurones whose energy metabolism is impaired from some primary pathological process. The 8 lines of evidence that primary or secondary excitotoxic mechanisms may be involved in the selective neuronal injury of MND are discussed. The evidence, while still circumstantial, is sufficient to warrant further research effort in this field, not least because the emergence of pharmacological agents which modify specific aspects of excitatory amino acid neurotransmission offer the possibility of therapeutic intervention in MND.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7807144     DOI: 10.1016/0022-510x(94)90170-8

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  14 in total

1.  T-588 protects motor neuron death against glutamate-induced neurotoxicity.

Authors:  Yasuo Iwasaki; Yasumitsu Ichikawa; Osamu Igarasi; Joe Aoyagi; Shingo Konno; Ken Ikeda; Hiroaki Iguchi; Seiichi Kawabe; Shigeki Marubuchi; Satoshi Ono
Journal:  Neurochem Res       Date:  2003-12       Impact factor: 3.996

2.  Two mechanisms of action of the adamantane derivative IEM-1460 at human AMPA-type glutamate receptors.

Authors:  Friedrich Schlesinger; Derk Tammena; Klaus Krampfl; Johannes Bufler
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

3.  The neuroprotectant properties of glutamate antagonists and antiglutamatergic drugs.

Authors:  V Pedersen; W J Schmidt
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 4.  Motor neuron disease: etiology, pathogenesis and treatment--a review.

Authors:  D J Donohoe; B Brady
Journal:  Ir J Med Sci       Date:  1996 Jul-Sep       Impact factor: 1.568

Review 5.  Neuroepidemiology of amyotrophic lateral sclerosis: clues to aetiology and pathogenesis.

Authors:  G C Román
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-08       Impact factor: 10.154

6.  Amyotrophic lateral sclerosis: from pathological mechanisms to patient care.

Authors:  G Scarlato
Journal:  J Neurol       Date:  1997-05       Impact factor: 4.849

7.  Synaptophysin in spinal anterior horn in aging and ALS: an immunohistological study.

Authors:  F F Cruz-Sánchez; A Moral; M L Rossi; L Quintó; C Castejón; E Tolosa; J de Belleroche
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 8.  Glutamate, excitotoxicity and amyotrophic lateral sclerosis.

Authors:  P J Shaw; P G Ince
Journal:  J Neurol       Date:  1997-05       Impact factor: 4.849

9.  Altered cortical activation during a motor task in ALS. Evidence for involvement of central pathways.

Authors:  Biba R Stanton; V C Williams; P N Leigh; Steven C R Williams; C R V Blain; J M Jarosz; Andrew Simmons
Journal:  J Neurol       Date:  2007-03-25       Impact factor: 4.849

10.  An investigation into the neuroprotective properties of ibuprofen.

Authors:  Z Lambat; N Conrad; S Anoopkumar-Dukie; R B Walker; S Daya
Journal:  Metab Brain Dis       Date:  2000-12       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.